881681-01-2
Chemical Structure
Vonoprazan Fumarate
Synonym(s): TAK-438
- CAS No.: 881681-01-2
- Formula:C21H20FN3O6S
- Molecular Weight:461.46
IUPAC Name: 1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamine fumarate
InChIKey: ROGSHYHKHPCCJW-WLHGVMLRSA-N
SMILES: OC(/C=C/C(O)=O)=O.O=S(N1C(C2=C(C=CC=C2)F)=CC(CNC)=C1)(C3=CN=CC=C3)=O
Biological Activity: Vonoprazan Fumarate (TAK-438), a proton pump inhibitor (PPI), is a potent and orally active potassium-competitive acid blocker (P-CAB), with antisecretory activity. Vonoprazan Fumarate inhibits H+,K+-ATPase activity in porcine gastric microsomes with an IC50 of 19 nM at pH 6.5. Vonoprazan Fumarate is developed for the research of acid-related diseases, such as gastroesophageal reflux disease and peptic ulcer disease[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Vonoprazan Fumarate | 99.92% | Vonoprazan Fumarate (TAK-438), a proton pump inhibitor (PPI), is a potent and orally active potassium-competitive acid blocker (P-CAB), with antisecretory activity. Vonoprazan Fumarate inhibits H+,K+-ATPase activity in porcine gastric microsomes with an IC50 of 19 nM at pH 6.5. Vonoprazan Fumarate is developed for the research of acid-related diseases, such as gastroesophageal reflux disease and peptic ulcer disease. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Vonoprazan Fumarate (Standard) | 99.99% | Vonoprazan (Fumarate) (Standard) is the analytical standard of Vonoprazan (Fumarate). This product is intended for research and analytical applications. Vonoprazan Fumarate (TAK-438), a proton pump inhibitor (PPI), is a potent and orally active potassium-competitive acid blocker (P-CAB), with antisecretory activity. Vonoprazan Fumarate inhibits H+,K+-ATPase activity in porcine gastric microsomes with an IC50 of 19 nM at pH 6.5. Vonoprazan Fumarate is developed for the research of acid-related diseases, such as gastroesophageal reflux disease and peptic ulcer disease. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
-
Similarity Score 0.85
HY-100007RVonoprazan (Standard) -
Similarity Score 0.85
HY-100007AVonoprazan hydrochloride -
Similarity Score 0.71
HY-W107196R5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrole-3-carbaldehyde (Standard) -
Similarity Score 0.70
HY-Z2335Vonoprazan impurity 1 -
Similarity Score 0.67
HY-153219P-CAB agent 2 hydrochloride -
Similarity Score 0.67
HY-153219AP-CAB agent 2 -
Similarity Score 0.66
HY-400540APadoprazanum fumarate -
Similarity Score 0.65
HY-176362S4-F-Benzenesulfonate-pyrrole(2-F-Ph)-methylamine-d3 -
Similarity Score 0.63
HY-180348KFP-H008 -
Explore the MedChemAI to find more analogs
References
- [1]. Arikawa Y, et al. Discovery of a novel pyrrole derivative 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine fumarate (TAK-438) as a potassium-competitive acid blocker (P-CAB). J Med Chem, 2012, 55(9), 4446-4456. [Content Brief]
- [2]. Hori Y, et al. 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases. J Pharmacol Exp Ther, 2010, 335(1), 231-238. [Content Brief]
